MedPath

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.eortc.be

E7070 in Treating Patients With Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2004-05-21
Last Posted Date
2012-07-11
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
30
Registration Number
NCT00003976
Locations
🇩🇪

Klinikum Nurnberg, Nuremberg (Nurnberg), Germany

🇫🇷

Institut Claudius Regaud, Toulouse, France

🇧🇪

Ludwig Institute for Cancer Research-Brussels Branch, Brussels, Belgium

and more 24 locations

Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases

Phase 3
Completed
Conditions
Metastatic Cancer
Prostate Cancer
First Posted Date
2004-05-20
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
204
Registration Number
NCT00002503
Locations
🇧🇪

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

🇳🇱

Academisch Ziekenhuis Groningen, Groningen, Netherlands

🇷🇺

Medical Radiological Research Center, Obninsk, Russian Federation

and more 18 locations

Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Phase 2
Terminated
Conditions
Bladder Cancer
First Posted Date
2004-05-20
Last Posted Date
2012-03-06
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
73
Registration Number
NCT00003640
Locations
🇮🇹

San Raffaele Hospital, Rome, Italy

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-20
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
39
Registration Number
NCT00003731
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇳🇱

Academisch Ziekenhuis Utrecht, Utrecht, Netherlands

and more 21 locations

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

Phase 1
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-17
Last Posted Date
2015-02-10
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
30
Registration Number
NCT00083096
Locations
🇫🇷

Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇫🇷

Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France

Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer

Phase 2
Completed
Conditions
Extragonadal Germ Cell Tumor
Ovarian Cancer
Testicular Germ Cell Tumor
First Posted Date
2004-05-13
Last Posted Date
2012-07-02
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
25
Registration Number
NCT00002903
Locations
🇩🇰

Herlev Hospital - University Hospital of Copenhagen, Herlev, Denmark

🇮🇹

Istituto Europeo Di Oncologia, Milano, Italy

🇮🇱

Rambam Medical Center, Haifa, Israel

and more 46 locations

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Phase 3
Completed
Conditions
Kidney Cancer
First Posted Date
2004-05-11
Last Posted Date
2012-07-11
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
320
Registration Number
NCT00002737
Locations
🇧🇪

Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium

🇧🇪

Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

🇳🇱

Groot Ziekengasthuis 's-Hertogenbosch, Hertogenbosch, Netherlands

and more 24 locations

Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2004-05-03
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
39
Registration Number
NCT00005055
Locations
🇫🇷

CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France

Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
First Posted Date
2004-05-03
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
96
Registration Number
NCT00004884
Locations
🇫🇷

Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France

🇩🇪

Praxis Innere Medizin, Neustadt, Germany

🇩🇪

Klinikum St. Marien, Amberg, Germany

and more 16 locations

Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
First Posted Date
2004-05-03
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
35
Registration Number
NCT00005053
Locations
🇳🇱

Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, Netherlands

🇮🇱

Rambam Medical Center, Haifa, Israel

🇨🇭

Inselspital, Bern, Bern, Switzerland

and more 12 locations
© Copyright 2025. All Rights Reserved by MedPath